SV

Street Verdict

Analyst Scorecard

GLENMARK · NSE

Glenmark Pharmaceuticals Limited

₹2,648

+1.51% (+₹39.5)

Prev. close

₹2,608.5

Volume

5,40,171

Delivery %

48.8%

As of

20 Nov 2026

Price history

₹2,648+₹343 (+14.88%) · 3M
18 Aug 2026 → 20 Nov 2026
2,2002,3002,4002,5002,60018 Aug09 Sept06 Oct29 Oct20 Nov
Daily closes · updates after each session

Analyst sentiment

Analysts lean bullish

2 analyst stances · last 90 days · one per analyst

Trackable

2 · 2 bull / 0 neutral / 0 bear

Long-Horizon

none in range

Commentary

none in range

Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded

Bullish 100% (2)Neutral 0% (0)Bearish 0% (0)
Explore by date range →

Analyst opinions

CallAnalystInstrumentVerdictActions
Market commentary · 6 · levels, conditionals, previews, macro & hedged views — context, not graded
CallAnalystInstrumentVerdictActions

Fundamentals

About Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited, together with its subsidiaries, research, develops, manufactures, and sells generics, specialty medicines, and over the counter (OTC) pharmaceutical products in India, North America, Europe, and internationally. The company provides various products in the therapeutic areas of dermatology, respiratory, oncology, cardiology, diabetes, gynecology, gastroenterology, and anti-infective in the dosage forms of complex injectables and biologics, oral solids, liquids, topical products, and respiratory-metered dose inhaler, dry powder inhaler, and nasal sprays. Its product pipeline includes ISB 2001, a CD38 x BCMA x CD3 trispecific T cell engager, which is in Phase 1 clinical trial for indication of multiple myeloma; ISB 2301, a Multispecific Immune Cell Activator that is in preclinical trial for solid tumors; ISB 2302, a bispecific immune modulator with an indication for hematologic and solid tumors; and ISB 2501, a trispecific T-cell engager indicated for solid tumors. The company's pipeline also comprises ISB 880, an IL-1RAP antagonist monoclonal antibody, which is in Phase 2 clinical trial for the treatment of hidradenitis suppurativa; and telazorlimab and ISB 830-X8, a OX40 antagonist mAb for the treatment of atopic dermatitis. In addition, the company offers Ryaltris, fixed-dose nasal spray for the treatment of allergic rhinitis. The company was incorporated in 1977 and is based in Mumbai, India.

Details

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

CEO

Mr. Glenn Mario Saldanha

Headquarters

Mumbai

Employees

16,946

Key stats

Market cap

₹70,350.14 Cr

P/E ratio (TTM)

39.6

Dividend yield

0.21%

EPS (TTM)

₹63.00

Beta (1Y · daily vs NIFTY 50)

0.91

Beta (5Y · monthly vs NIFTY 50)

0.90

Shares float

15.02 Cr

EPS · quarter ended Jun 2026

₹17.11

Financial Performance

01 · Financials

-20000 Cr0 Cr20000 Cr₹-20%-10%0%10%FY21FY22FY23FY24FY25FY26
RevenueNet incomeEBITDANet income ÷ revenue

02 · Earnings Per Share (EPS)

-100-50050₹FY21FY22FY23FY24FY25FY26

03 · Dividend Profile

0123₹0%25%50%75%100%17 Sept 2008 Sept 2112 Sept 2218 Sept 2313 Sept 2415 Sept 2503 Oct 2531 Aug 26
Dividend (₹/share)Annualised yieldAnnual dividend growth (FY)

Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.

04 · Operating Efficiency (Growth Rates)

Balance-sheet-based

-50%0%50%100%FY21FY22FY23FY24FY25FY26
SalesFixed assetsTrade receivablesInventory

05 · Capital Structure & Asset Utilization

0 Cr5000 Cr10000 Cr15000 Cr20000 Cr₹0×0.25×0.5×0.75×1×FY21FY22FY23FY24FY25FY26
Total assetsTotal debtDebt / equityAsset turnover

Asset turnover needs a prior year of assets — omitted for the earliest available year.

06 · Asset Base Composition

0 Cr5000 Cr10000 Cr15000 Cr20000 Cr₹FY21FY22FY23FY24FY25FY26
Fixed assetsCurrent assetsOther assets

07 · Debt Level & Coverage

-2500 Cr0 Cr2500 Cr5000 Cr₹FY21FY22FY23FY24FY25FY26
DebtFree cash flowCash & equivalents

08 · Profit & Loss

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹10,943.93 Cr₹12,304.90 Cr₹11,431.94 Cr₹11,813.10 Cr₹13,321.74 Cr₹16,982.51 Cr
EBITDA
₹2,179.14 Cr₹2,226.06 Cr₹1,200.15 Cr₹1,183.27 Cr₹2,092.28 Cr₹2,766.95 Cr
₹970.09 Cr₹941.71 Cr₹297.25 Cr₹-1,501.67 Cr₹1,047.10 Cr₹1,361.85 Cr
Diluted EPS
₹34.38₹33.37₹10.53₹-53.22₹37.1₹48.24

Net income for Mar 2021 could not be checked against the company's own annual report: this page shows ₹970.09 Cr while the annual report gives ₹1,649.45 Cr (70.0% apart).

EBITDA for Mar 2021 could not be checked against the company's own annual report: this page shows ₹2,179.14 Cr while the annual report gives ₹2,360.47 Cr (8.3% apart).

09 · Balance Sheet

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹15,575.00 Cr₹17,052.00 Cr₹19,371.00 Cr₹14,358.00 Cr₹15,991.00 Cr₹19,907.00 Cr
—₹3,962.02 Cr₹4,607.88 Cr₹1,230.93 Cr₹2,472.67 Cr₹593.53 Cr
Stockholders' equity
₹7,064.00 Cr₹9,086.00 Cr₹9,474.00 Cr₹7,848.00 Cr₹8,849.00 Cr₹10,512.00 Cr

Current assets, Cash & equivalents, Non-current assets, Others, Total debt, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — the missing years are left blank rather than estimated.

Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.

10 · Cash Flow Statement

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹1,131.00 Cr₹1,109.00 Cr₹625.00 Cr₹-265.00 Cr₹-828.00 Cr₹3,445.00 Cr
Investing cash flow
₹-675.24 Cr₹-333.28 Cr₹-528.49 Cr₹4,560.89 Cr₹2.09 Cr₹-1,283.23 Cr
₹-442.00 Cr₹-520.00 Cr₹-77.00 Cr₹-3,906.00 Cr₹787.00 Cr₹-2,709.00 Cr
Capital expenditure
₹-775.00 Cr₹-790.00 Cr₹-608.00 Cr₹-898.00 Cr₹-751.00 Cr₹-1,358.00 Cr
End cash position
₹1,138.10 Cr₹1,410.53 Cr₹1,443.03 Cr₹1,658.27 Cr₹1,675.71 Cr₹1,174.71 Cr

Debt issued, Debt repaid have filed figures for only some of the years shown — the missing years are left blank rather than estimated.

Annual only — the data source has no quarterly cash-flow-statement coverage.

11 · Shareholding Pattern

NSE, quarterly

Line itemSep 20Sep 21–Dec 23(10Q)Mar 24Jun 24–Jun 26(9Q)
Promoter46.63%46.65%46.64%46.65%
Public53.37%53.35%53.36%53.35%
Employee trusts0.00%0.00%0.00%0.00%

Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.

12 · Peer Comparison

Healthcare

Company
Sun Pharmaceutical Industries Limited₹4.25 L Cr₹1,769.938.85.0913.7%0.06+11.9%+3.7%
Divi's Laboratories Limited₹2.66 L Cr₹10,037.590.815.8515.3%0.00+12.3%+47.5%
Torrent Pharmaceuticals Limited₹1.79 L Cr₹4,738.579.421.3125.8%1.79+21.5%+32.5%
Laurus Labs Limited₹1.27 L Cr₹2,34894.823.9416.8%0.48+22.0%+146.2%
Apollo Hospitals Enterprise Limited₹1.23 L Cr₹8,599.558.812.9520.5%0.90+15.7%+10.1%
Zydus Lifesciences Limited₹1.19 L Cr₹1,188.126.74.4018.6%0.46+18.4%+22.3%
Lenskart Solutions Limited₹1.16 L Cr₹689.7181.413.305.6%0.35+35.4%—
Dr. Reddy's Laboratories Limited₹1.14 L Cr₹1,37440.63.0211.4%0.21+3.2%+14.5%
Cipla Limited₹1.13 L Cr₹1,40238.93.2711.3%0.02+2.1%-6.7%
Mankind Pharma Limited₹1.03 L Cr₹2,47545.96.3111.7%0.39+17.0%+3.1%
Aurobindo Pharma Limited₹98,101.93 Cr₹1,70526.62.599.2%0.21+6.4%+48.4%
Glenmark Pharmaceuticals Limited₹70,350.14 Cr₹2,504.739.66.6913.0%0.06+27.1%+35.7%

Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.

GLENMARK

Glenmark Pharma shares rise over 2% as unit files US application for experimental solid-tumour drug

Moneycontrol.com · 5 days ago

GLENMARK

Glenmark shares gain 2% to ₹2,673 after IND filing for first in class pentaspecific cancer antibody ISB 2301

Business Upturn · 5 days ago